Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX008 vs Chemotherapy in First-Line MSI-H/dMMR Metastatic Colorectal Cancer
NCT05652894Phase 3Active, not recruiting
- Sponsor
- Taizhou Hanzhong Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial of pucotenlimab in colorectal cancer (CRC) (2 arms), sponsored by Taizhou Hanzhong Pharmaceuticals. Primary endpoint: Progression-free Survival by IRC at 2 years. Started Feb 2023; status: active, not recruiting.
02
Drugs
pucotenlimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05652894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652894.